Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …

Most patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) experience
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …

Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive
breast and gastric cancers, and are emerging as potential treatments for HER2-positive …